712:
margin of the modified intent-to-treat (MITT) and clinically evaluable (CE) patient populations. Clinical cure rates in the MITT population were 92.4% and 91.6% for eravacycline (n=250) and meropenem (n=249), respectively (95% CI: -4.1%,5.8%). Clinical cure rates in the CE population were 96.9% and 96.1% for eravacycline (n=225) and meropenem (n=231), respectively (95% CI: -2.9%,4.5%). Eravacycline met the primary efficacy endpoints according to the FDA and EMA guidelines. The secondary analyses were consistent with, and supportive of, the primary outcome according to
Tetraphase. There were no treatment-related serious adverse events (SAEs) in the trial. Treatment-emergent adverse event (TEAEs) rates were similar in both treatment groups with the most commonly reported drug-related adverse events (AEs) for eravacycline were infusion site reactions, nausea and vomiting, each occurring at a rate of less than 5%. The most common Gram-negative pathogens in the study included
776:. The primary endpoints are Proportion of Participants in the microbiological Intent-to-treat (micro-ITT) Population demonstrating Clinical Cure and Microbiologic Success at the End of Intravenous (EOI) Visit & Proportion of Participants in the micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit . With secondary endpoints(outcomes) testing Proportion of Participants in the microbiological Modified Intent-To-Treat (micro-MITT) Population and the Microbiologically Evaluable (ME) Population Demonstrating Microbiologic Success at the TOC Visit
22:
62:
2307:
708:(1g every 8 hours). The study enrolled 500 adult patients with the primary endpoint being clinical response at the test-of-cure visit which is 25–31 days after initial dosing. Primary efficiency analysis was conducted using a 12.5% non-inferiority margin in the microbiological intent-to-treat (micro-ITT) population.
767:
IGNITE3 is currently ongoing starting
January 2017 with expected completion December 2018. This study is evaluating IV eravacycline (1.5 mg/kg every 24 hours) compared to ertapenem (1g every 24 hours) for the treatment of cUTI. IGNITE3 is currently enrolling approximately 1,000 patients who will
830:
Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. (16 November 2016). "Assessing the
Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized
747:
The IGNITE 2 trial compared 7 days of IV eravacycline to IV levofloxacin with the option to convert patients in either group to oral therapy after 3 days for cUTI. Overall, eravacyline was inferior to levofloxacin in response rate (60.4 vs 66.9%); however it was noted that patients who completed
711:
In July 2017, Tetraphase pharmaceuticals released top line data via press showing clinical cure rates in the micro-ITT population to be 90.8% and 91.2% for eravacycline (n=195) and meropenem (n=205), respectively (95% CI: -6.3%,5.3%). Primary analysis was conducted using a 12.5% non-inferiority
695:
The IGNITE 1 trial compared twice-daily IV eravacycline to once-daily ertapenem for the treatment of cIAI. A total of 541 patients were included and eravacycline demonstrated noninferiority to ertapenem. An additional pivotal phase 3 study (IGNITE 4) is planned for late 2016 with initial results
150:
748:
therapy with the IV formulation had higher response rates, suggesting formulation issues with the oral option. Due to the performance of the IV formulation, an additional phase 3 trial is planned to support a supplemental NDA for the cUTI indication.
265:
InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34,36-37,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1
1348:
1226:
728:. Full data from IGNITE4 will become available as the company prepares to submit its New Drug Application (NDA) in the first quarter of 2018 for Eravacycline treatment of Complicated Intra-abdominal Infections.
435:
strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) were recently completed with mixed results. Eravacycline was granted
1054:"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections"
1465:
1378:"Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections - Full Text View - ClinicalTrials.gov"
944:
Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. (1 April 2016). "Review of
Eravacycline, a Novel Fluorocycline Antibacterial Agent".
452:
Eravacycline has shown broad spectrum of activity against a variety of Gram-positive and Gram-negative bacteria, including multi-drug resistant strains, such as
1458:
915:
347:
1451:
1324:"Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections - Full Text View - ClinicalTrials.gov"
1111:"Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City"
1291:"Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections (NASDAQ:TTPH)"
281:
453:
670:
1406:"Tetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI (NASDAQ:TTPH)"
1405:
1290:
1255:
885:
1443:
461:
784:
Eravacycline is under development by
Tetraphase Pharmaceuticals Inc. It is marketed under trade name Xerava in United States.
2261:
95:)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9--1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
2332:
517:
256:
1377:
2278:
997:"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens"
704:
IGNITE 4 assessed twice-daily intravenous eravacycline(1.0 mg/kg every 12 hours) compared to those receiving
397:
2327:
886:"Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI (NASDAQ:TTPH)"
367:
1323:
916:"FDA Grants QIDP Designation to Eravacycline, Tetraphase's Lead Antibiotic Product Candidate | Business Wire"
1256:"Tetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status (NASDAQ:TTPH)"
1052:
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. (1 January 2014).
538:
441:
233:
1478:
1966:
1870:
1521:
2297:
2210:
1729:
1438:
498:
432:
1473:
1168:"Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1"
2266:
531:
1439:
Process R&D of
Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development
1612:
545:
170:
2337:
583:
559:
552:
505:
490:
126:
1919:
1413:
1298:
801:
512:
242:
74:
1263:
893:
8:
1548:
621:
116:
35:
Please help update this article to reflect recent events or newly available information.
1203:
1143:
1110:
1086:
1053:
1029:
996:
977:
864:
591:
565:
2190:
2186:
1755:
1208:
1190:
1167:
1148:
1130:
1091:
1073:
1034:
1016:
969:
961:
856:
848:
614:
222:
981:
868:
2238:
2182:
1810:
1198:
1182:
1138:
1122:
1081:
1065:
1024:
1008:
953:
840:
571:
437:
358:
304:
1498:
1349:"IGNITE2: Eravacycline inferior to levofloxacin, but IV formulation shows promise"
2311:
2229:
2224:
1936:
1805:
1800:
630:
Similar to other tetracycline derivatives, eravacycline is poorly active against
1494:
1490:
1486:
1482:
2272:
2089:
2019:
2004:
1765:
1650:
1638:
1516:
1227:"Phase 3 IGNITE4 trial to examine safety, efficacy of IV eravacycline in cIAIs"
1166:
Fyfe C, LeBlanc G, Close B, Nordmann P, Dumas J, Grossman TH (22 August 2016).
1109:
Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J (1 March 2015).
844:
576:
464:. It is currently being formulated as for intravenous and oral administration.
391:
957:
2321:
2234:
2178:
2170:
2132:
2122:
2094:
2074:
2064:
2059:
2024:
2009:
1946:
1941:
1865:
1830:
1618:
1194:
1134:
1077:
1020:
965:
852:
289:
CN(C)12C3CC4=C(C=C(C(=C4C(=O)C3=C(2(C(=O)C(=C1O)C(=O)N)O)O)O)NC(=O)CN5CCCC5)F
2218:
2214:
2142:
2079:
2049:
2014:
1984:
1820:
1795:
1780:
1760:
1734:
1675:
1623:
1570:
1543:
1533:
1212:
1152:
1095:
1038:
973:
860:
773:
598:
420:
353:
772:
for a minimum of 5 days, and will then be eligible for transition to oral
2204:
2150:
2127:
2054:
2039:
2034:
1951:
1838:
1815:
1790:
1785:
1775:
1750:
1594:
1565:
1186:
1126:
1069:
1012:
654:
606:
428:
417:
61:
2200:
2160:
2155:
2104:
2084:
2069:
2044:
1999:
1994:
1928:
1899:
1879:
1699:
1694:
1685:
1680:
1665:
1660:
1608:
1560:
1474:
424:
331:
161:
2029:
1989:
1976:
1909:
1904:
1894:
1889:
1884:
1715:
1670:
1633:
1628:
1599:
1589:
1579:
769:
705:
699:
679:
390:
Except where otherwise noted, data are given for materials in their
2114:
1584:
1555:
658:
197:
190:
751:
731:
149:
2099:
209:
1051:
995:
Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH (1 November 2013).
994:
2196:
650:
139:
1108:
829:
181:
943:
1856:
1507:
768:
be randomized 1:1 to receive intravenous eravacycline or
1165:
427:
by
Tetraphase Pharmaceuticals. It is closely related to
2295:
431:. It has a broad spectrum of activity including many
494:(both methicillin-resistant and sensitive strains)
700:Complicated Intra-abdominal Infections (IGNITE 4)
680:Complicated Intra-abdominal infections (IGNITE 1)
649:activity against Enterobacteriaceae carrying the
2319:
696:likely available in the fourth quarter of 2017.
221:
752:Complicated Urinary Tract Infections (IGNITE 3)
732:Complicated Urinary Tract infections (IGNITE 2)
125:
1459:
669:Current and past clinical trial information:
1927:
1466:
1452:
524:
483:
169:
1202:
1142:
1085:
1028:
779:
241:
587:(including carbapenem resistant strains)
467:
462:carbapenem-resistant Enterobacteriaceae
2320:
376:
1447:
1400:
1398:
1372:
1370:
1318:
1316:
1285:
1283:
1281:
1250:
1248:
1175:Antimicrobial Agents and Chemotherapy
1115:Antimicrobial Agents and Chemotherapy
1058:Antimicrobial Agents and Chemotherapy
1001:Antimicrobial Agents and Chemotherapy
268:Key: HLFSMUUOKPBTSM-ISIOAQNYSA-N
939:
937:
880:
878:
825:
823:
357:
15:
444:and is currently available in USA.
212:
196:
189:
13:
1395:
1367:
1313:
1278:
1245:
664:
14:
2349:
1432:
934:
875:
820:
674:
2305:
641:16 mcg/mL (range 0.06-64 mcg/mL)
60:
20:
1341:
1219:
447:
394:(at 25 °C , 100 kPa).
1967:transpeptidation/translocation
1159:
1102:
1045:
988:
908:
794:
1:
787:
539:Stenotrophomonas maltophilia
7:
10:
2354:
845:10.1001/jamasurg.2016.4237
2256:
2211:Quinupristin/dalfopristin
2169:
2141:
2113:
1975:
1964:
1918:
1864:
1855:
1829:
1743:
1728:
1708:
1647:
1530:
1515:
1506:
1479:inhibit protein synthesis
958:10.1007/s40265-016-0545-8
806:European Medicines Agency
388:
340:
297:
277:
252:
109:
101:
73:
68:
59:
29:This article needs to be
2333:1-Pyrrolidinyl compounds
1730:Tetracycline antibiotics
499:Streptococcus pneumoniae
645:Eravacycline maintains
532:Acinetobacter baumannii
525:Gram-negative organisms
484:Gram-positive organisms
2328:Polyketide antibiotics
780:Commercial information
632:Pseudomonas aeruginosa
546:Haemophilus influenzae
454:methicillin-resistant
718:Klebsiella pneumoniae
653:gene responsible for
584:Klebsiella pneumoniae
560:Neisseria gonorrhoeae
553:Moraxella catarrhalis
506:Enterococcus faecalis
491:Staphylococcus aureus
456:Staphylococcus aureus
336:558.555
1920:Peptidyl transferase
1187:10.1128/AAC.01646-16
1127:10.1128/AAC.04809-14
1070:10.1128/AAC.01614-13
1013:10.1128/AAC.01288-13
518:vancomycin resistant
513:Enterococcus faecium
468:Spectrum of activity
433:multi-drug resistant
75:Preferred IUPAC name
1549:Dihydrostreptomycin
1266:on 21 November 2016
896:on 21 November 2016
622:Serratia marcescens
579:-producing strains)
440:designation by the
56:
2283:Never to phase III
1382:clinicaltrials.gov
1328:clinicaltrials.gov
592:Klebsiella oxytoca
566:Enterobacteriaceae
398:Infobox references
54:
2293:
2292:
2252:
2251:
2248:
2247:
1960:
1959:
1851:
1850:
1847:
1846:
1756:Chlortetracycline
1724:
1723:
1233:. 19 October 2016
1181:(11): 6989–6990.
1007:(11): 5548–5558.
831:Clinical Trial".
615:Proteus mirabilis
416:) is a synthetic
406:Chemical compound
404:
403:
380:
151:Interactive image
50:
49:
2345:
2310:
2309:
2308:
2301:
1973:
1972:
1925:
1924:
1862:
1861:
1811:Rolitetracycline
1741:
1740:
1528:
1527:
1513:
1512:
1468:
1461:
1454:
1445:
1444:
1426:
1425:
1423:
1421:
1416:on 7 August 2017
1412:. Archived from
1402:
1393:
1392:
1390:
1388:
1374:
1365:
1364:
1362:
1360:
1345:
1339:
1338:
1336:
1334:
1320:
1311:
1310:
1308:
1306:
1301:on 1 August 2017
1297:. Archived from
1287:
1276:
1275:
1273:
1271:
1262:. Archived from
1252:
1243:
1242:
1240:
1238:
1223:
1217:
1216:
1206:
1172:
1163:
1157:
1156:
1146:
1121:(3): 1802–1805.
1106:
1100:
1099:
1089:
1064:(4): 1847–1854.
1049:
1043:
1042:
1032:
992:
986:
985:
941:
932:
931:
929:
927:
920:businesswire.com
912:
906:
905:
903:
901:
892:. Archived from
882:
873:
872:
827:
818:
817:
815:
813:
808:. 8 October 2018
798:
764:
763:
759:
744:
743:
739:
714:Escherichia coli
692:
691:
687:
572:Escherichia coli
480:
479:
475:
378:
375:
361:
305:Chemical formula
245:
225:
214:
200:
193:
173:
153:
129:
64:
57:
53:
45:
42:
36:
24:
23:
16:
2353:
2352:
2348:
2347:
2346:
2344:
2343:
2342:
2318:
2317:
2316:
2306:
2304:
2296:
2294:
2289:
2288:
2273:Clinical trials
2244:
2230:Streptogramin B
2225:Streptogramin A
2165:
2137:
2109:
1956:
1937:Chloramphenicol
1914:
1868:
1843:
1825:
1806:Penimepicycline
1801:Oxytetracycline
1732:
1720:
1704:
1643:
1519:
1517:Aminoglycosides
1502:
1472:
1435:
1430:
1429:
1419:
1417:
1404:
1403:
1396:
1386:
1384:
1376:
1375:
1368:
1358:
1356:
1347:
1346:
1342:
1332:
1330:
1322:
1321:
1314:
1304:
1302:
1289:
1288:
1279:
1269:
1267:
1254:
1253:
1246:
1236:
1234:
1225:
1224:
1220:
1170:
1164:
1160:
1107:
1103:
1050:
1046:
993:
989:
942:
935:
925:
923:
914:
913:
909:
899:
897:
884:
883:
876:
828:
821:
811:
809:
800:
799:
795:
790:
782:
765:
761:
757:
755:
754:
745:
741:
737:
735:
734:
702:
693:
689:
685:
683:
682:
677:
667:
665:Clinical trials
637:
527:
486:
481:
477:
473:
471:
470:
450:
407:
400:
395:
384:
350:
325:
321:
317:
313:
307:
293:
290:
285:
284:
273:
270:
269:
266:
260:
259:
248:
228:
215:
203:
176:
156:
143:
132:
119:
105:
97:
96:
46:
40:
37:
34:
25:
21:
12:
11:
5:
2351:
2341:
2340:
2335:
2330:
2315:
2314:
2291:
2290:
2287:
2286:
2285:
2284:
2281:
2270:
2264:
2258:
2257:
2254:
2253:
2250:
2249:
2246:
2245:
2243:
2242:
2232:
2227:
2222:
2208:
2194:
2175:
2173:
2171:Streptogramins
2167:
2166:
2164:
2163:
2158:
2153:
2147:
2145:
2139:
2138:
2136:
2135:
2130:
2125:
2119:
2117:
2111:
2110:
2108:
2107:
2102:
2097:
2092:
2090:Troleandomycin
2087:
2082:
2077:
2072:
2067:
2062:
2057:
2052:
2047:
2042:
2037:
2032:
2027:
2022:
2020:Flurithromycin
2017:
2012:
2007:
2005:Clarithromycin
2002:
1997:
1992:
1987:
1981:
1979:
1970:
1962:
1961:
1958:
1957:
1955:
1954:
1949:
1944:
1939:
1933:
1931:
1922:
1916:
1915:
1913:
1912:
1907:
1902:
1897:
1892:
1887:
1882:
1876:
1874:
1859:
1853:
1852:
1849:
1848:
1845:
1844:
1842:
1841:
1835:
1833:
1831:Glycylcyclines
1827:
1826:
1824:
1823:
1818:
1813:
1808:
1803:
1798:
1793:
1788:
1783:
1778:
1773:
1768:
1766:Demeclocycline
1763:
1758:
1753:
1747:
1745:
1738:
1726:
1725:
1722:
1721:
1719:
1718:
1712:
1710:
1706:
1705:
1703:
1702:
1697:
1691:
1690:
1689:
1688:
1683:
1678:
1673:
1668:
1657:
1655:
1651:Micromonospora
1645:
1644:
1642:
1641:
1639:Nourseothricin
1636:
1631:
1626:
1621:
1616:
1605:
1604:
1603:
1602:
1597:
1592:
1587:
1576:
1575:
1574:
1573:
1568:
1563:
1552:
1551:
1546:
1540:
1538:
1525:
1510:
1504:
1503:
1475:Antibacterials
1471:
1470:
1463:
1456:
1448:
1442:
1441:
1434:
1433:External links
1431:
1428:
1427:
1394:
1366:
1340:
1312:
1277:
1244:
1218:
1158:
1101:
1044:
987:
952:(5): 567–588.
933:
922:. 15 July 2013
907:
874:
839:(3): 224–232.
819:
792:
791:
789:
786:
781:
778:
753:
750:
733:
730:
701:
698:
681:
678:
676:
675:Phase 3 trials
673:
666:
663:
635:
628:
627:
626:
625:
618:
611:
603:
595:
588:
580:
563:
556:
549:
542:
535:
526:
523:
522:
521:
509:
502:
495:
485:
482:
469:
466:
449:
446:
405:
402:
401:
396:
392:standard state
389:
386:
385:
383:
382:
372:
370:
364:
363:
351:
346:
343:
342:
338:
337:
334:
328:
327:
323:
319:
315:
311:
308:
303:
300:
299:
295:
294:
292:
291:
288:
280:
279:
278:
275:
274:
272:
271:
267:
264:
263:
255:
254:
253:
250:
249:
247:
246:
238:
236:
230:
229:
227:
226:
218:
216:
208:
205:
204:
202:
201:
194:
186:
184:
178:
177:
175:
174:
166:
164:
158:
157:
155:
154:
146:
144:
137:
134:
133:
131:
130:
122:
120:
115:
112:
111:
107:
106:
103:
99:
98:
78:
77:
71:
70:
66:
65:
48:
47:
28:
26:
19:
9:
6:
4:
3:
2:
2350:
2339:
2336:
2334:
2331:
2329:
2326:
2325:
2323:
2313:
2303:
2302:
2299:
2282:
2280:
2277:
2276:
2274:
2271:
2268:
2265:
2263:
2260:
2259:
2255:
2240:
2236:
2235:Virginiamycin
2233:
2231:
2228:
2226:
2223:
2220:
2216:
2212:
2209:
2206:
2202:
2198:
2195:
2192:
2188:
2184:
2180:
2179:Pristinamycin
2177:
2176:
2174:
2172:
2168:
2162:
2159:
2157:
2154:
2152:
2149:
2148:
2146:
2144:
2140:
2134:
2133:Solithromycin
2131:
2129:
2126:
2124:
2123:Telithromycin
2121:
2120:
2118:
2116:
2112:
2106:
2103:
2101:
2098:
2096:
2095:Tulathromycin
2093:
2091:
2088:
2086:
2083:
2081:
2078:
2076:
2075:Telithromycin
2073:
2071:
2068:
2066:
2065:Solithromycin
2063:
2061:
2060:Roxithromycin
2058:
2056:
2053:
2051:
2048:
2046:
2043:
2041:
2038:
2036:
2033:
2031:
2028:
2026:
2025:Gamithromycin
2023:
2021:
2018:
2016:
2013:
2011:
2010:Dirithromycin
2008:
2006:
2003:
2001:
1998:
1996:
1993:
1991:
1988:
1986:
1983:
1982:
1980:
1978:
1974:
1971:
1968:
1963:
1953:
1950:
1948:
1947:Thiamphenicol
1945:
1943:
1942:Azidamfenicol
1940:
1938:
1935:
1934:
1932:
1930:
1926:
1923:
1921:
1917:
1911:
1908:
1906:
1903:
1901:
1898:
1896:
1893:
1891:
1888:
1886:
1883:
1881:
1878:
1877:
1875:
1872:
1867:
1866:Oxazolidinone
1863:
1860:
1858:
1854:
1840:
1837:
1836:
1834:
1832:
1828:
1822:
1819:
1817:
1814:
1812:
1809:
1807:
1804:
1802:
1799:
1797:
1794:
1792:
1789:
1787:
1784:
1782:
1779:
1777:
1774:
1772:
1769:
1767:
1764:
1762:
1759:
1757:
1754:
1752:
1749:
1748:
1746:
1744:Tetracyclines
1742:
1739:
1736:
1731:
1727:
1717:
1714:
1713:
1711:
1707:
1701:
1698:
1696:
1693:
1692:
1687:
1684:
1682:
1679:
1677:
1674:
1672:
1669:
1667:
1664:
1663:
1662:
1659:
1658:
1656:
1653:
1652:
1646:
1640:
1637:
1635:
1632:
1630:
1627:
1625:
1622:
1620:
1619:Spectinomycin
1617:
1614:
1610:
1607:
1606:
1601:
1598:
1596:
1593:
1591:
1588:
1586:
1583:
1582:
1581:
1578:
1577:
1572:
1569:
1567:
1564:
1562:
1559:
1558:
1557:
1554:
1553:
1550:
1547:
1545:
1542:
1541:
1539:
1536:
1535:
1529:
1526:
1523:
1518:
1514:
1511:
1509:
1505:
1500:
1496:
1492:
1488:
1484:
1480:
1476:
1469:
1464:
1462:
1457:
1455:
1450:
1449:
1446:
1440:
1437:
1436:
1415:
1411:
1410:ir.tphase.com
1407:
1401:
1399:
1383:
1379:
1373:
1371:
1355:. 8 July 2016
1354:
1350:
1344:
1329:
1325:
1319:
1317:
1300:
1296:
1295:ir.tphase.com
1292:
1286:
1284:
1282:
1265:
1261:
1260:ir.tphase.com
1257:
1251:
1249:
1232:
1228:
1222:
1214:
1210:
1205:
1200:
1196:
1192:
1188:
1184:
1180:
1176:
1169:
1162:
1154:
1150:
1145:
1140:
1136:
1132:
1128:
1124:
1120:
1116:
1112:
1105:
1097:
1093:
1088:
1083:
1079:
1075:
1071:
1067:
1063:
1059:
1055:
1048:
1040:
1036:
1031:
1026:
1022:
1018:
1014:
1010:
1006:
1002:
998:
991:
983:
979:
975:
971:
967:
963:
959:
955:
951:
947:
940:
938:
921:
917:
911:
895:
891:
890:ir.tphase.com
887:
881:
879:
870:
866:
862:
858:
854:
850:
846:
842:
838:
834:
826:
824:
807:
803:
802:"Xerava EPAR"
797:
793:
785:
777:
775:
771:
760:
749:
740:
729:
727:
723:
719:
715:
709:
707:
697:
688:
672:
671:
662:
660:
656:
652:
648:
644:
640:
633:
624:
623:
619:
617:
616:
612:
609:
608:
604:
601:
600:
596:
594:
593:
589:
586:
585:
581:
578:
574:
573:
569:
568:
567:
564:
562:
561:
557:
555:
554:
550:
548:
547:
543:
541:
540:
536:
534:
533:
529:
528:
519:
515:
514:
510:
508:
507:
503:
501:
500:
496:
493:
492:
488:
487:
476:
465:
463:
459:
457:
445:
443:
439:
434:
430:
426:
422:
419:
415:
411:
399:
393:
387:
381: Rx-only
374:
373:
371:
369:
366:
365:
360:
355:
352:
349:
345:
344:
341:Pharmacology
339:
335:
333:
330:
329:
309:
306:
302:
301:
296:
287:
286:
283:
276:
262:
261:
258:
251:
244:
240:
239:
237:
235:
232:
231:
224:
220:
219:
217:
211:
207:
206:
199:
195:
192:
188:
187:
185:
183:
180:
179:
172:
168:
167:
165:
163:
160:
159:
152:
148:
147:
145:
141:
136:
135:
128:
124:
123:
121:
118:
114:
113:
108:
100:
94:
90:
86:
82:
76:
72:
67:
63:
58:
55:Eravacycline
52:
44:
41:November 2018
32:
27:
18:
17:
2338:Fluoroarenes
2219:Quinupristin
2215:Dalfopristin
2143:Lincosamides
2080:Tildipirosin
2050:Oleandomycin
2015:Erythromycin
1985:Azithromycin
1821:Tetracycline
1796:Omadacycline
1781:Meclocycline
1771:Eravacycline
1770:
1761:Clomocycline
1676:Micronomicin
1649:
1624:Hygromycin B
1613:+loteprednol
1571:Ribostamycin
1544:Streptomycin
1534:Streptomyces
1532:
1418:. Retrieved
1414:the original
1409:
1385:. Retrieved
1381:
1357:. Retrieved
1352:
1343:
1331:. Retrieved
1327:
1303:. Retrieved
1299:the original
1294:
1268:. Retrieved
1264:the original
1259:
1235:. Retrieved
1230:
1221:
1178:
1174:
1161:
1118:
1114:
1104:
1061:
1057:
1047:
1004:
1000:
990:
949:
945:
924:. Retrieved
919:
910:
898:. Retrieved
894:the original
889:
836:
833:JAMA Surgery
832:
810:. Retrieved
805:
796:
783:
774:levofloxacin
766:
746:
725:
721:
717:
713:
710:
703:
694:
668:
661:resistance.
646:
642:
638:
631:
629:
620:
613:
605:
599:Enterobacter
597:
590:
582:
570:
558:
551:
544:
537:
530:
511:
504:
497:
489:
455:
451:
448:Medical uses
421:tetracycline
413:
410:Eravacycline
409:
408:
368:Legal status
127:1207283-85-9
110:Identifiers
102:Other names
92:
88:
84:
80:
51:
38:
30:
2269:from market
2205:Linopristin
2151:Clindamycin
2128:Cethromycin
2055:Rokitamycin
2040:Midecamycin
2035:Kitasamycin
1952:Florfenicol
1929:Amphenicols
1873:inhibitors)
1839:Tigecycline
1816:Sarecycline
1791:Minocycline
1786:Metacycline
1776:Lymecycline
1751:Doxycycline
1595:Bekanamycin
1566:Paromomycin
1524:inhibitors)
1270:20 November
926:20 November
900:20 November
726:Bacteroides
722:Pseudomonas
655:polymyxin b
607:Citrobacter
575:(including
516:(including
429:tigecycline
418:halogenated
298:Properties
2322:Categories
2201:Flopristin
2161:Pirlimycin
2156:Lincomycin
2105:Tylvalosin
2085:Tilmicosin
2070:Spiramycin
2045:Miocamycin
2000:Carrimycin
1995:Carbomycin
1977:Macrolides
1900:Ranbezolid
1880:Eperezolid
1871:initiation
1700:Astromicin
1695:Verdamicin
1686:Isepamicin
1681:Plazomicin
1666:Netilmicin
1661:Gentamicin
1609:Tobramycin
1561:Framycetin
1522:initiation
1359:16 January
1237:16 January
788:References
634:with a MIC
438:fast track
425:antibiotic
332:Molar mass
243:07896928ZC
162:ChemSpider
138:3D model (
117:CAS Number
2279:Phase III
2267:Withdrawn
2115:Ketolides
2030:Josamycin
1990:Boromycin
1910:Tedizolid
1905:Sutezolid
1895:Radezolid
1890:Posizolid
1885:Linezolid
1716:Butirosin
1671:Sisomicin
1634:Apramycin
1629:Totomycin
1600:Dibekacin
1590:Arbekacin
1580:Kanamycin
1195:0066-4804
1135:1098-6596
1078:1098-6596
1021:1098-6596
966:1179-1950
853:2168-6262
770:ertapenem
706:meropenem
412:(TP-434,
2312:Medicine
1737:binding)
1648:-micin (
1585:Amikacin
1556:Neomycin
1531:-mycin (
1213:27550359
1153:25534744
1096:24342651
1039:23979750
982:36285428
974:26863149
869:42977246
861:27851857
659:colistin
647:in-vitro
520:strains)
362:)
348:ATC code
223:54726192
171:28495485
2100:Tylosin
1420:27 July
1387:27 July
1333:27 July
1305:27 July
1204:5075126
1144:4325809
1087:4023720
1030:3811277
812:29 June
610:species
602:species
356: (
354:J01AA13
326:
210:PubChem
31:updated
2298:Portal
2262:WHO-EM
2197:NXL103
1499:QJ01XQ
1353:Healio
1231:Healio
1211:
1201:
1193:
1151:
1141:
1133:
1094:
1084:
1076:
1037:
1027:
1019:
980:
972:
964:
867:
859:
851:
756:": -->
736:": -->
684:": -->
472:": -->
458:(MRSA)
423:class
414:Xerava
282:SMILES
198:D10421
191:D10369
104:Xerava
69:Names
1965:MLS (
1709:other
1477:that
1171:(PDF)
978:S2CID
946:Drugs
865:S2CID
651:mcr-1
257:InChI
140:JSmol
1735:tRNA
1495:J01G
1491:J01F
1487:J01B
1483:J01A
1422:2017
1389:2017
1361:2023
1335:2017
1307:2017
1272:2016
1239:2023
1209:PMID
1191:ISSN
1149:PMID
1131:ISSN
1092:PMID
1074:ISSN
1035:PMID
1017:ISSN
970:PMID
962:ISSN
928:2016
902:2016
857:PMID
849:ISSN
814:2024
758:edit
738:edit
724:and
686:edit
577:ESBL
474:edit
460:and
234:UNII
182:KEGG
91:,12a
2191:IIB
2187:IIA
1857:50S
1508:30S
1199:PMC
1183:doi
1139:PMC
1123:doi
1082:PMC
1066:doi
1025:PMC
1009:doi
954:doi
841:doi
837:152
442:FDA
359:WHO
213:CID
87:,5a
83:,4a
2324::
2275::
2239:S1
2217:,
2203:,
2189:,
2185:,
2183:IA
1497:,
1493:,
1489:,
1485:,
1408:.
1397:^
1380:.
1369:^
1351:.
1326:.
1315:^
1293:.
1280:^
1258:.
1247:^
1229:.
1207:.
1197:.
1189:.
1179:60
1177:.
1173:.
1147:.
1137:.
1129:.
1119:59
1117:.
1113:.
1090:.
1080:.
1072:.
1062:58
1060:.
1056:.
1033:.
1023:.
1015:.
1005:57
1003:.
999:.
976:.
968:.
960:.
950:76
948:.
936:^
918:.
888:.
877:^
863:.
855:.
847:.
835:.
822:^
804:.
720:,
716:,
636:90
377:EU
318:FN
316:31
312:27
79:(4
2300::
2241:)
2237:(
2221:)
2213:(
2207:)
2199:(
2193:)
2181:(
1969:)
1869:(
1733:(
1654:)
1615:)
1611:(
1537:)
1520:(
1501:)
1481:(
1467:e
1460:t
1453:v
1424:.
1391:.
1363:.
1337:.
1309:.
1274:.
1241:.
1215:.
1185::
1155:.
1125::
1098:.
1068::
1041:.
1011::
984:.
956::
930:.
904:.
871:.
843::
816:.
762:]
742:]
690:]
657:/
643:.
639:=
478:]
379::
324:8
322:O
320:4
314:H
310:C
142:)
93:S
89:R
85:S
81:S
43:)
39:(
33:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
